about
Drug-Induced Metabolic AcidosisThe safety of rofecoxibA dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty ratEpoxides and soluble epoxide hydrolase in cardiovascular physiologyCyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular functionSuccinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney.Renal cortical regulation of COX-1 and functionally related products in early renovascular hypertension (rat).Eicosanoids, β-cell function, and diabetesAngiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain.Cardiovascular risk and COX-2 inhibition in rheumatological practice.Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense.Effects of lornoxicam and intravenous ibuprofen on erythrocyte deformability and hepatic and renal blood flow in rats.Hypertension, kidney, and transgenics: a fresh perspective.Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility.A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.Redox control of renal function and hypertension.Activation of the succinate receptor GPR91 in macula densa cells causes renin release.Enhanced pressor response to acute Ang II infusion in mice lacking membrane-associated prostaglandin E2 synthase-1.Renal adverse effects of nonsteroidal anti-inflammatory drugs.Prostaglandin E2 modulation of blood pressure homeostasis: studies in rodent models.A review of the efficacy, safety, and cost-effectiveness of COX-2 inhibitors for Africa and the Middle East region.Hypertension: physiology and pathophysiology.Renal medullary circulation.Cytochrome P450 and Lipoxygenase Metabolites on Renal Function.Clinical safety and efficacy of NG440: a novel combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid for inflammatory conditions.Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain.The effects of calcineurin inhibitors on prostanoid synthesis: a randomized cross-over study in healthy humans.20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis?Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension.Angiotensin II-induced calcium signaling in the afferent arteriole from rats with two-kidney, one-clip hypertension.Effect of celecoxib on the antihypertensive effect of losartan in a rat model of renovascular hypertension.Cyclooxygenase 2: protein-protein interactions and posttranslational modifications.Effect of kefir and low-dose aspirin on arterial blood pressure measurements and renal apoptosis in unhypertensive rats with 4 weeks salt diet.Changes in extracellular matrix composition regulate cyclooxygenase-2 expression in human mesangial cells.Effects of a Single Dose of Parecoxib on Inflammatory Response and Ischemic Tubular Injury Caused by Hemorrhagic Shock in Rats.Urinary nitric oxide metabolites and individual blood pressure progression to overt hypertensionThe Study of Pyridazine Compounds on Prostanoids: Inhibitors of COX, cAMP Phosphodiesterase, and TXA2Synthase
P2860
Q26766204-7C9CE17A-C85D-4518-AF44-41545C2E7646Q28176535-00B79FBE-33FB-4E87-A0E4-BC63590F6A68Q28390006-ECDF0503-4233-4EDC-8104-39E0AD15594AQ28396313-0CC2D855-376C-491C-AEAB-1FD58AE6F2A8Q30477135-2BA4FDC8-1167-4462-BC55-9BE6C0EDE1DEQ30482204-CB920C61-F351-461D-B395-433359F44CE3Q33247383-A226040D-35B3-465F-96AA-5FE8201C5ADAQ35129888-085B1084-02ED-44AC-A03E-396302144727Q35838537-434B032C-9DBB-4402-B801-F45C290134D5Q35896154-19167B36-E9B9-4C59-9B21-E939EE8B7796Q35925625-EBE6E342-F619-4CAA-A870-4BE4AB780E8DQ36075305-ABC71F0F-4720-45F7-973F-E031DA97479BQ36106476-C491F818-FB48-4FDE-89E8-B1925B79917CQ36443015-E28D949D-DAFF-43B5-B314-18D8245E98A6Q36591447-83D4E402-2916-4876-9BC2-B126E4B56BF6Q36823364-FC7F6B6F-03BA-4D84-94DF-497CB726C729Q36970633-CBB1E1C1-73A1-4413-8D90-EC3BDD850992Q37181984-A9900202-E4CE-4A17-B880-CCA6645F44E8Q37492595-632CCA77-56B3-43E3-BBF3-C35902221A1FQ37615395-FC79B953-7C2D-402A-B9F3-C0E68AB5BA48Q37908321-39F7BCAA-FEB7-4A4C-8744-02097270C219Q38038881-CDAB23D0-B1E6-49F4-9BF8-5D4305E88285Q38110492-97B099C8-7894-4243-93B4-EDF4FCF9B5BEQ38111278-6D3BBE62-C06A-4C41-A87C-48B6188F465DQ38693289-FA0D69A1-D64D-4111-BE51-FDF5F86EF171Q39326522-913E7AA8-05BB-4651-9F87-54E6D02836C7Q39499131-746AD1EB-ED21-4BCD-B91D-09CD2E8670A4Q42516874-D86F28BA-7BA6-4A7E-9AFF-C0A8D121B1C3Q44932438-ADB0D7DD-6B72-40E8-9F27-956F4813272EQ46226259-A794AFD2-9126-44F1-AA82-C8880A138455Q46918475-43F65C70-4C1C-45E8-8CA5-8A200A7B3C71Q46935027-3BDDEEDC-6CCA-40CE-ABE3-25A2C1A7CD34Q46991087-A3D88C33-2B07-4EA8-B20B-92FA91CF73BEQ47758719-DB13ABDE-EFA9-4A4B-97AB-3F88808E216DQ51029579-31DAEDE8-944D-4BAE-9B6B-BB8A4AA52611Q54622127-317067D5-1CCE-4445-B968-F3AE87CAB6C7Q55048490-F87AD59C-0B27-4418-996B-A15F0D0D6DAAQ57085400-0588E90F-EC09-434A-84F8-D260E98FE053Q59054771-722D652D-5D48-40AD-84EE-80E8C2394D00
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cyclooxygenases, the kidney, and hypertension.
@ast
Cyclooxygenases, the kidney, and hypertension.
@en
type
label
Cyclooxygenases, the kidney, and hypertension.
@ast
Cyclooxygenases, the kidney, and hypertension.
@en
prefLabel
Cyclooxygenases, the kidney, and hypertension.
@ast
Cyclooxygenases, the kidney, and hypertension.
@en
P1433
P1476
Cyclooxygenases, the kidney, and hypertension.
@en
P2093
Hui-Fang Cheng
Raymond C Harris
P304
P356
10.1161/01.HYP.0000116221.27079.EA
P407
P577
2004-01-19T00:00:00Z